A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03522246 |
Recruitment Status :
Active, not recruiting
First Posted : May 11, 2018
Last Update Posted : September 15, 2023
|
Sponsor:
pharmaand GmbH
Collaborators:
Bristol-Myers Squibb
Gynecologic Oncology Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Foundation Medicine
Information provided by (Responsible Party):
pharmaand GmbH
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | December 30, 2024 |
Estimated Study Completion Date : | December 30, 2030 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):